JPH03852B2 - - Google Patents

Info

Publication number: JPH03852B2
Authority: JP; Japan
Prior art keywords: urokinase; absorbable; higher fatty; fatty acid; composition according
Prior art date: 1983-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP58203683A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6097917A (ja

Inventor

Fujio Nakagame

Haruo Pponda

Tetsupei Maruyama

Noriko Saito

Tomoaki Kimoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Terumo Corp

Original Assignee

Terumo Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-01

Filing date

1983-11-01

Publication date

1991-01-09

1983-11-01 Application filed by Terumo Corp filed Critical Terumo Corp

1983-11-01 Priority to JP58203683A priority Critical patent/JPS6097917A/ja

1984-10-09 Priority to US06/659,228 priority patent/US4615885A/en

1984-10-09 Priority to EP84112090A priority patent/EP0143949B1/de

1984-10-09 Priority to DE8484112090T priority patent/DE3474511D1/de

1985-05-31 Publication of JPS6097917A publication Critical patent/JPS6097917A/ja

1991-01-09 Publication of JPH03852B2 publication Critical patent/JPH03852B2/ja

Status Granted legal-status Critical Current

Links

102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 78
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 78
229960005356 urokinase Drugs 0.000 claims description 78
239000000203 mixture Substances 0.000 claims description 39
235000014113 dietary fatty acids Nutrition 0.000 claims description 26
239000000194 fatty acid Substances 0.000 claims description 26
229930195729 fatty acid Natural products 0.000 claims description 26
150000004665 fatty acids Chemical class 0.000 claims description 26
239000002502 liposome Substances 0.000 claims description 21
229920001515 polyalkylene glycol Polymers 0.000 claims description 16
159000000007 calcium salts Chemical class 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 12
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 8
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 8
239000005642 Oleic acid Substances 0.000 claims description 8
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 8
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 8
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
229920001223 polyethylene glycol Polymers 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000012528 membrane Substances 0.000 claims description 4
239000000463 material Substances 0.000 claims description 3
239000002775 capsule Substances 0.000 description 31
239000008280 blood Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
230000000694 effects Effects 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
210000001035 gastrointestinal tract Anatomy 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 6
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 5
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 5
239000002702 enteric coating Substances 0.000 description 5
238000009505 enteric coating Methods 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
229960002713 calcium chloride Drugs 0.000 description 4
235000011148 calcium chloride Nutrition 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
239000002504 physiological saline solution Substances 0.000 description 4
229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 3
239000000829 suppository Substances 0.000 description 3
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
239000004375 Dextrin Substances 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
229960001714 calcium phosphate Drugs 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000021313 oleic acid Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000010409 thin film Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000005303 weighing Methods 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
229940122791 Plasmin inhibitor Drugs 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000004227 calcium gluconate Substances 0.000 description 1
235000013927 calcium gluconate Nutrition 0.000 description 1
229960004494 calcium gluconate Drugs 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002468 fat body Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
239000010408 film Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002806 plasmin inhibitor Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP58203683A 1983-11-01 1983-11-01 腸管吸収性ウロキナ−ゼ組成物 Granted JPS6097917A (ja)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP58203683A JPS6097917A (ja)	1983-11-01	1983-11-01	腸管吸収性ウロキナ−ゼ組成物
US06/659,228 US4615885A (en)	1983-11-01	1984-10-09	Pharmaceutical composition containing urokinase
EP84112090A EP0143949B1 (de)	1983-11-01	1984-10-09	Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
DE8484112090T DE3474511D1 (en)	1983-11-01	1984-10-09	Pharmaceutical composition containing urokinase

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58203683A JPS6097917A (ja)	1983-11-01	1983-11-01	腸管吸収性ウロキナ−ゼ組成物

Publications (2)

Publication Number	Publication Date
JPS6097917A JPS6097917A (ja)	1985-05-31
JPH03852B2 true JPH03852B2 (de)	1991-01-09

Family

ID=16478108

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58203683A Granted JPS6097917A (ja)	1983-11-01	1983-11-01	腸管吸収性ウロキナ−ゼ組成物

Country Status (1)

Country	Link
JP (1)	JPS6097917A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60215633A (ja) *	1984-04-11	1985-10-29	Terumo Corp	腸管吸収性ウロキナ−ゼリポソ−ム組成物
IL77186A0 (en) *	1985-11-29	1986-04-29	Touitou Elka	Pharmaceutical insulin composition
ES2130056B1 (es) *	1997-01-16	2000-02-01	Lipotec Sa	Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.

1983
- 1983-11-01 JP JP58203683A patent/JPS6097917A/ja active Granted

Also Published As

Publication number	Publication date
JPS6097917A (ja)	1985-05-31

Publication	Publication Date	Title
EP0143949B1 (de)	1988-10-12	Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
KR100210359B1 (ko)	1999-07-15	경구용 글리코스아미노글리칸을 함유하는 의약 조성물
FI93608B (fi)	1995-01-31	Menetelmä ksantaanikumia sisältävän, kiinteän lääkevalmisteen valmistamiseksi
JPS6232166B2 (de)	1987-07-13
JPS6354684B2 (de)	1988-10-28
PT1432408E (pt)	2010-12-07	Composições farmacêuticas que compreendem dióxido de silício coloidal
BRPI0608853B1 (pt)	2020-05-19	composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
JPH02500669A (ja)	1990-03-08	薬物送達システム
SE453797B (sv)	1988-03-07	Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt
PL200957B1 (pl)	2009-02-27	Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
JP2003531849A (ja)	2003-10-28	グアイフェネシン徐放製剤および錠剤
CN100389751C (zh)	2008-05-28	含扑热息痛的吞咽片剂
JP2931409B2 (ja)	1999-08-09	パラセタモール及びドンペリドンのフィルムコーティング錠
JP4405156B2 (ja)	2010-01-27	プロリポソーム薬物送達システム
MXPA03006404A (es)	2004-12-02	Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
TW200820995A (en)	2008-05-16	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JPH03852B2 (de)	1991-01-09
JP2511577B2 (ja)	1996-06-26	アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
JPH0324452B2 (de)	1991-04-03
US6245354B1 (en)	2001-06-12	Drug delivery system using galactoxyloglucan
JP2688603B2 (ja)	1997-12-10	血栓溶解剤
JPS649293B2 (de)	1989-02-16
BR112012018696B1 (pt)	2019-07-02	Composição farmacêutica com atividade antiobesidade compreendendo uma pré-mistura de orlistat puro e processo de preparação
GB2336999A (en)	1999-11-10	High-dosage triclosan compositions
AU721632B2 (en)	2000-07-13	Agent for preventing restenosis